The New Jersey mother is celebrating the “amazing” new drugs that will stop the illness on that orbit, eight years after receiving the crushing diagnosis.
Active runner and mother of two, Raziel Green, 52, was diagnosed with a rare ALS in 2017.
The former retail manager began experiencing symptoms over a decade ago. This was told to Fox News Digital during an on-camera interview when my feet started to feel heavy during a normally easy run.
ALS new drugs eligible for rapid FDA approval
“A few months later, I began to struggle to climb the stairs in my house,” she recalled.
A few months later, when Green began experiencing balance issues and muscle loss, she decided to meet a neurologist.
Raziel Green, 52, an active runner and mother of two (pictured with her child), was diagnosed with a rare ALS in 2017. (Rajiel Green)
Knowing that both her mother and aunt had been diagnosed with a rare form of ALS, Greene sought more opinions and tests. It wasn't until she saw the third neurologist who specialised in genetics that she was diagnosed with the superoxide dismutase 1 (SOD1) gene and amyotrophic lateral sclerosis (ALS).
According to the ALS Association, the disease caused by mutations in the SOD1 gene accounts for approximately 10% to 20% of genetic ALS cases and 1% to 2% of sporadic ALS cases.
Service dogs help boys with rare genetic disorders achieve “incredible” advancements
Shortly after her diagnosis, Green learned about clinical trials at Mass General for the experimental drug Qalsody® (Tofersen), created by Biogen in Cambridge, Massachusetts.
The medication is administered to the spinal fluid via lumbar puncture every few weeks.
“Drugs target DNA, so if given quickly enough, they could be cured, but we can assume that these trials have not yet been conducted.”
“I was lucky enough to be given the opportunity and be part of the trial,” she said.
“I really wanted to do this for me and my family as well as others who have this form of ALS, knowing we have genes.”
“It gives my child the opportunity to get tested and have this medication as a preventative treatment,” Green said of the drug Qalsody. (Rajiel Green)
Within four months, Greene saw a “big difference” and said it hadn't gotten worse since.
“I looked at the neurologist and she compared notes from now onwards seven years ago, but she can't see anything different from the day I was diagnosed.”
Profits and risks
QALSODY is specifically designed to treat SOD1 type of ALS by reducing the toxic effects of mutations in the SOD1 gene.
Family selling dream home to fund a life-saving treatment for 5-year-old daughter
“Around 20% to 25% of people with SOD1 ALS treated with Qalsody not only showed slowing progression, but also showed signs of progression completely stopped or improvement,” a doctor who was not involved in Green's care told Fox News Digital.
Dr. Thomas Purvis, a neurologist at the Rockefeller Institute of Neuroscience at West Virginia University, called Tofersen, one of the “most exciting medicines” of ALS in recent years.
The former retail manager began experiencing symptoms over a decade ago. This was told to Fox News Digital when my legs started to feel heavy on a normally simple run. (Rajiel Green)
The benefits seen during the 28-week trial period are “slightly modest,” he said, but said patients began to look and feel better over the long term.
“This is common in clinical trials for chronic diseases. I told Purvis, who was not involved in Green's care because they appreciate the benefits when treated patients are followed for longer periods of time.
“Drugs target DNA, so if given quickly enough, they could be cured, but we can assume that these trials have not yet been conducted.”
Diagnosis of a rare disease strengthens the bond between twin sisters: “We do our best”
Several side effects were observed in a small number of patients who took Qalsody.
“Around 7% of people treated with QALSODY in clinical trials had serious side effects, including osteomyelitis (spinal cord inflammation), neuroticitis (neuralgia), increased intracranial pressure, and more,” shares Fox News Digital.
Green is a photo of her embracing her son in one of his hockey games. Greene She said her medication allowed her children to participate in sports competitions, graduations and other milestones. (Rajiel Green)
According to Purvis, some rare effects included severe headaches, weakness and loss of sensation.
“Finally, after exposing patients to these treatments, they don’t know the long-term outcomes in a few decades.
Click here to sign up for our health newsletter
“However, current data appears to teach that treatments are safe in the long term.”
Stephanie Fradette, Pharm.D. , head of the Neuromuscular Development Unit at Biogen (manufactured by Qalsody), noted that in the Phase 3 courage study, participants treated with Qalsody experienced a 55% reduction in plasma neurofilament levels, a marker of neurodegeneration, compared to a 12% increase in participants per plant.
Today, Green uses a full-time cane and wheelchair over long distances, but given that her symptoms haven't gotten worse, she can still do much of what she enjoys. (Rajiel Green)
“Looking ahead to what we see next in the ALS research, our work with SOD1-ALS shows that it is possible to slow down the catastrophic neurodegeneration that occurs in this disease,” Fradette told Fox News Digital.
“We continue to apply lessons from recent research on SOD1-AL and studies we have done over the past decade, helping to bring safe and effective treatments to the broader ALS community.”
“I want to continue”
Greene expressed her gratitude for the opportunity to obtain a Qalsody, which is now approved by the US Food and Drug Administration (FDA) and is available to anyone who has been diagnosed with this particular genetic mutation.
“I can still travel. I can still stand up. I am still independent in my daily activities.”
Every 28 days, Green receives her medication.
Today, she has a somewhat limited mobility. She uses a cane full time and uses a wheelchair over long distances, but considering her symptoms haven't gotten worse, Green can still do many of the things she enjoys.
“When patients undergoing treatment are followed for a longer period, the benefits are better evaluated,” one doctor said. Green, depicted here with her son, said that there has been no difference in her condition since the neurologist started Qalsody. (Rajiel Green)
“I can still travel. I can still stand up. I'm still independent in my daily activities,” she told Fox News Digital. “When someone comes along, I still go to the gym sometimes.”
Visit us for more health articles www.foxnews.com/health
Greene was also able to participate in children's athletic competitions, graduations and other milestones.
The drug “hopes to continue” with Green and other patients with the same genes, she said.
Click here to get the Fox News app
“And it gives my kids the opportunity to get tested and have this medication as a preventative treatment,” Green continued. “That was my main goal. After receiving treatment, I will remain stable.”
